Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative
(polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal
cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of
macrogol 3350-based oral osmotic laxative may stop cancer from growing in patients who are at
risk of colorectal cancer.